SCHEMBL10150837

SCHEMBL10150837

O=C(OCC12CC3CC(CC(O)(C3)C1)C2)C(F)(F)S(=O)(=O)O/N=C(/c1ccccc1)C(F)(F)F

nearest known ligand 0.37

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 4/20 0.37
PDK2 Q15119 4/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
P2RX7 Q99572 1/20 0.32
DPP8 Q6V1X1 2/20 0.31
DPP9 Q86TI2 2/20 0.31
ALDH1A1 P00352 1/20 0.31
LMNA P02545 1/20 0.31
MAPT P10636 1/20 0.30
HPGD P15428 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10150841 0.91 P2RX7 (0.32) SCN9AP2RX7DPP8DPP9
SCHEMBL10150823 0.91 P2RX7 (0.38) SCN9AP2RX7ALDH1A1LMNA
SCHEMBL14839328 0.81 SCN9A (0.37) SCN9AP2RX7ALDH1A1
SCHEMBL15659577 0.80 SCN9A (0.38) SCN9APDK2L3MBTL1P2RX7DPP8
SCHEMBL17063683 0.80 SCN9A (0.38) SCN9APDK2L3MBTL1P2RX7DPP8
SCHEMBL14839337 0.78 SCN9A (0.32) SCN9AALDH1A1
SCHEMBL16669093 0.76 SCN9A (0.38) SCN9AL3MBTL1ALDH1A1MAPTHPGD
SCHEMBL17068038 0.76 SCN9A (0.40) SCN9AL3MBTL1ALDH1A1MAPTHPGD
SCHEMBL30029494 0.76 SCN9A (0.37) SCN9APDK2L3MBTL1P2RX7DPP8
SCHEMBL525455 0.76 SCN9A (0.37) SCN9APDK2L3MBTL1P2RX7DPP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173350-B2 Oxime compound and resist composition containing the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-05-08 US disclosed
US-20100021847-A1 Oxime Compound and Resist Composition Containing the Same SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100021847-A1 Oxime Compound and Resist Composition Containing the Same CYC1, UQCRB, CBR1 SCN9A 1835/4885PDK2 1355/4885L3MBTL1 1811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.